Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.
about
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionSoluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responsesLgr4/Gpr48 negatively regulates TLR2/4-associated pattern recognition and innate immunity by targeting CD14 expressionPersistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects.Microbial translocation: a marker of advanced HIV-1 infection and a predictor of treatment failure?Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIVHost Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals.Monocyte signal transduction receptors in active and latent tuberculosisTwo-Year Follow-up Study of Mycobacterium tuberculosis Antigen-Driven IFN-γ Responses and Macrophage sCD14 Levels After Tuberculosis Contact.Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosisMMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.Relationship of salivary CD14 concentration with dental caries in young childrenPlasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients.Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus.Estimation of sCD14 levels in saliva obtained from patients with various periodontal conditions.Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta2-microglobulin, respectively.Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis.Partners in crime: co-infections in the developing world
P2860
Q24550678-0DC4148F-2A7A-4E14-B2BE-7ED0969FA204Q28534690-B9391922-E1D7-4621-B50F-539D7CCD9AB3Q28591315-6CC258E2-AF92-43B9-94F9-0C10D6A8152EQ34143557-9A72D59D-154E-4357-8019-DD999ACF60C0Q34772738-D7DA8049-07E8-4694-A8E1-BD7E5B1BB956Q35766808-EB403CCA-68B8-4CF8-8991-6E31D0F0F164Q36106333-60050A23-D5B6-4670-88C1-E168630571C1Q36582615-3822C2A1-91CC-47A0-AAD0-A43713A11B2FQ37173974-57C5AD4C-B3B8-4127-B08D-D2D9A0C15626Q37272336-BE7BA651-F0E3-422D-959C-3A082A1FA8F3Q40219795-E751744A-A62F-4D98-B432-3A258476372DQ41706750-DA377B99-FBC5-4A72-8ECD-7D488BE082E1Q41920055-2B86767D-1253-4D98-845D-8EF03A75D807Q42318292-1A75C4CC-7F87-4B4E-8912-E5CD0560B48BQ45737966-48F35D91-238D-4860-9778-9FB8B8282F94Q45908855-A23E5BEB-0DD1-419F-A64D-3C3F96F40532Q46264440-31D3893D-DB18-4019-8CFD-DC3D7C2D5967Q52679098-72B826A1-D82E-4613-8AF9-CA8820CF133BQ56920473-DC31633C-36F4-4DA0-9F09-5DB00B09495B
P2860
Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@en
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@nl
type
label
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@en
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@nl
prefLabel
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@en
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@nl
P2093
P2860
P1476
Elevated serum concentrations ...... g anti-tuberculosis treatment.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2249.2000.01246.X
P577
2000-06-01T00:00:00Z